TVG CEO, Jeremy Salt, discusses the recent successful completion of the Streptococcus suis and transmissible Lassa fever vaccine projects.

Most emerging infectious diseases affecting humans in the last century originated in animal reservoirs and are defined as zoonotic. Lassa fever is a significant zoonotic disease

TVG has completed a successful Anglo-Chinese project backed by the Department of Health and Social Care (DHSC), Innovate UK, and the Chinese Ministry of Science and

As TVG prepares for future growth a new position of Laboratory Manager has been created and we are delighted to announce that after an extensive recruitment

The Vaccine Group is proud to announce that Dr Michael Jarvis, TVG’s Chief Scientific Officer, has been recognised in the 2021 NIH Director’s Awards. Dr Jarvis

Trial data show strong T cell responses to SARS-CoV-2, as well as the more divergent SARS-CoV-1, demonstrating potential for broad immunity against current and future variants

The Vaccine Group (“TVG” or the “Company”) is pleased to announce the appointment of Dr Jeremy Salt as Chief Executive Officer. Jeremy has extensive experience in senior roles in

The Vaccine Group (“TVG” or the “Company”) today announces it is to collaborate with The Pirbright Institute  (“Pirbright” or the “Institute”)  to develop vaccine candidates to